Hostname: page-component-78c5997874-mlc7c Total loading time: 0 Render date: 2024-11-17T14:05:31.514Z Has data issue: false hasContentIssue false

Ethyl-eicosapentaenoic acid in bipolar depression

Published online by Cambridge University Press:  02 January 2018

I. Upton*
Affiliation:
Ashworth Hospital, Parkbourn, Liverpool L31 1HW, UK. Email: [email protected]
Rights & Permissions [Opens in a new window]

Abstract

Type
Columns
Copyright
Copyright © 2006 The Royal College of Psychiatrists 

Frangou et al (Reference Frangou, Lewis and McCrone2006) reported ethyleicosapentaenoic acid (ethyl-EPA) to be effective in the treatment of bipolar depression. However, no mention is made of the dietary intake of ethyl-EPA among the randomised groups. Ethyl-EPA is a naturally occurring substance and hence a potential confounding variable. The statistically significant improvements in the ethyl-EPA group(s) compared with placebo in terms of decreases in scores on the Hamilton Rating Scale for Depression and the Clinical Global Impression Scale could simply have been a result of differences in dietary ethyl-EPA intake. Such a difference is likely to have involved increased intake in the ethyl-EPA group(s), but decreased intake in these groups could have lessened any potential improvements. Further studies of omega-3 fatty acids must control for the potential confounding independent variable of dietary intake.

References

Frangou, S., Lewis, M. & McCrone, P. (2006) Efficacy of ethyl-eicosapentaenoic acid in bipolar depression: randomised double-blind placebo-controlled study. British Journal of Psychiatry, 188, 4650.CrossRefGoogle ScholarPubMed
Submit a response

eLetters

No eLetters have been published for this article.